$115.54▼ 1.13 (0.97%)
Real-time prices · US Markets78% of 27 covering analysts have a positive rating.
Quality
5.7
Health
7
Growth
5.5
Valuation
6.8
Sentiment
7.8
Analyst Target
$120.20
▲ +4.0% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
37.4×
price-to-earnings
Forward P/E
19.1×
next 12 months est.
Market Cap
$199.9B
market capitalization
Div Yield
2.16%
dividend yield
Profit Margin
11.6%
net profit margin
Gross Margin
56.8%
revenue minus COGS
ROE
10.6%
return on equity
Beta
0.58
vs S&P 500
52-Week Range
$82 — $137
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Abbott Laboratories right now?
Abbott Laboratories's Q·Score is 6.5/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. 78% of 27 covering analysts have a positive rating. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for ABT?
The consensus price target for ABT is $120.20, based on ratings from 25 Wall Street analysts. This is 4.0% above the current price of $115.54. Price targets are forward-looking estimates and not guarantees of future performance.
Is ABT overvalued or undervalued?
Abbott Laboratories (ABT) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 19.1×.
When does Abbott Laboratories report its next earnings?
Abbott Laboratories's next earnings report is expected on approximately October 14, 2026.
What is Abbott Laboratories's profit margin?
Abbott Laboratories has a net profit margin of 11.6%, which is solid for most industries. Its gross margin stands at 56.8%, indicating a high-margin business model.
What is ABT's dividend yield?
Abbott Laboratories currently offers a dividend yield of 2.16%, which is above the typical market average dividend yield. Dividend yields can change based on price movements and company payout decisions.
Is Abbott Laboratories's revenue growing?
Abbott Laboratories is reporting solid revenue growth of 13.0% year-over-year. However, earnings declined 47.5%, which warrants monitoring.
How much debt does Abbott Laboratories have?
Abbott Laboratories has a debt-to-equity ratio of 0.63×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 1.38×, suggesting it should be monitored for near-term liquidity.
Compare ABT with any stock